Grants and Contributions:
Title:
Preclinical Characterization and Validation of Novel Inhibitors for CNS Disease
Agreement Number:
981188
Agreement Value:
$250,000.00
Agreement Date:
Oct 15, 2021 - Jun 30, 2022
Description:
The project will characterize and validate novel small molecule glucocerebrosidase 2 inhibitors as disease-modifying therapeutics for Parkinson’s disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5A 4B5
Reference Number:
172-2021-2022-Q3-981188
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
851456152
Recipient Type:
For-profit organization
Recipient's Legal Name:
Alectos Therapeutics Inc.
Federal Riding Name:
Burnaby North--Seymour
Federal Riding Number:
59002
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710